197 related articles for article (PubMed ID: 21723985)
1. GLP-1-based therapies: the dilemma of uncertainty.
Spranger J; Gundert-Remy U; Stammschulte T
Gastroenterology; 2011 Jul; 141(1):20-3. PubMed ID: 21723985
[No Abstract] [Full Text] [Related]
2. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
Xu L; Spinas GA; Niessen M
Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
[No Abstract] [Full Text] [Related]
3. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Elashoff M; Matveyenko AV; Gier B; Elashoff R; Butler PC
Gastroenterology; 2011 Jul; 141(1):150-6. PubMed ID: 21334333
[TBL] [Abstract][Full Text] [Related]
4. Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting.
Lando HM; Alattar M; Dua AP
Endocr Pract; 2012; 18(4):472-7. PubMed ID: 22440997
[TBL] [Abstract][Full Text] [Related]
5. The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits.
Ryder RE
Diabet Med; 2013 Oct; 30(10):1148-55. PubMed ID: 24073725
[TBL] [Abstract][Full Text] [Related]
6. Exenatide and sitagliptin: pancreatitis and pancreatic cancer. Harms on the rise.
Prescrire Int; 2011 Nov; 20(121):267. PubMed ID: 22066314
[No Abstract] [Full Text] [Related]
7. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
Drucker DJ; Nauck MA
Lancet; 2006 Nov; 368(9548):1696-705. PubMed ID: 17098089
[TBL] [Abstract][Full Text] [Related]
8. An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Harja E; Lord J; Skyler JS
Diabetes Technol Ther; 2013 Aug; 15(8):609-18. PubMed ID: 23927624
[TBL] [Abstract][Full Text] [Related]
9. Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
Iyer SN; Drake AJ; West RL; Mendez CE; Tanenberg RJ
Endocr Pract; 2012; 18(1):e10-3. PubMed ID: 22068258
[TBL] [Abstract][Full Text] [Related]
10. Two drugs for type 2 diabetes seem to raise risk of acute pancreatitis, study shows.
Cohen D
BMJ; 2013 Feb; 346():f1304. PubMed ID: 23447395
[No Abstract] [Full Text] [Related]
11. Pancreatitis associated with incretin-based therapies.
Iyer SN; Tanenberg RJ; Mendez CE; West RL; Drake AJ
Diabetes Care; 2013 Apr; 36(4):e49. PubMed ID: 23520376
[No Abstract] [Full Text] [Related]
12. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Singh S; Chang HY; Richards TM; Weiner JP; Clark JM; Segal JB
JAMA Intern Med; 2013 Apr; 173(7):534-9. PubMed ID: 23440284
[TBL] [Abstract][Full Text] [Related]
13. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
14. Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
Engel SS; Williams-Herman DE; Golm GT; Clay RJ; Machotka SV; Kaufman KD; Goldstein BJ
Int J Clin Pract; 2010 Jun; 64(7):984-90. PubMed ID: 20412332
[TBL] [Abstract][Full Text] [Related]
15. [Therapeutic use and adverse events of incretin-related drugs].
Ishikawa M; Yamada Y
Nihon Rinsho; 2012 May; 70 Suppl 3():699-702. PubMed ID: 22768601
[No Abstract] [Full Text] [Related]
16. One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Aston-Mourney K; Subramanian SL; Zraika S; Samarasekera T; Meier DT; Goldstein LC; Hull RL
Am J Physiol Endocrinol Metab; 2013 Aug; 305(4):E475-84. PubMed ID: 23736544
[TBL] [Abstract][Full Text] [Related]
17. Journal withdraws article after complaints from drug manufacturers.
Hawkes N
BMJ; 2011 Apr; 342():d2335. PubMed ID: 21482597
[No Abstract] [Full Text] [Related]
18. [Treatment with new preparations against type 2 diabetes not sufficiently documented].
Karlsson EA; Palmér M; Malmström R
Lakartidningen; 2008 Feb 27-Mar 4; 105(9):647-8; author reply 648-9. PubMed ID: 18376713
[No Abstract] [Full Text] [Related]
19. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Aroda VR; Ratner R
Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.
Madsbad S; Krarup T; Deacon CF; Holst JJ
Curr Opin Clin Nutr Metab Care; 2008 Jul; 11(4):491-9. PubMed ID: 18542012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
